DOCSLIB.ORG

Ribonuclease H, an Unexploited Target for Antiviral Intervention Against HIV and Hepatitis B Virus T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ribonuclease H, an Unexploited Target for Antiviral Intervention Against HIV and Hepatitis B Virus T Antiviral Research 171 (2019) 104613 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Article Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus T ∗∗ ∗ Enzo Tramontanoa, , Angela Coronaa, Luis Menéndez-Ariasb, a Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy b Centro de Biología Molecular “Severo Ochoa” (Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid), Madrid, Spain ARTICLE INFO ABSTRACT Keywords: Ribonucleases H (RNases H) are endonucleolytic enzymes, evolutionarily related to retroviral integrases, DNA Ribonuclease H transposases, resolvases and numerous nucleases. RNases H cleave RNA in RNA/DNA hybrids and their activity Reverse transcriptase plays an important role in the replication of prokaryotic and eukaryotic genomes, as well as in the replication of HIV reverse-transcribing viruses. During reverse transcription, the RNase H activity of human immunodeficiency Hepatitis B virus virus (HIV) and hepatitis B virus (HBV) degrades the viral genomic RNA to facilitate the synthesis of viral Antiviral double-stranded DNA. HIV and HBV reverse transcriptases contain DNA polymerase and RNase H domains that act in a coordinated manner to produce double-stranded viral DNA. Although RNase H inhibitors have not been developed into licensed drugs, recent progress has led to the identification of a number of small molecules with inhibitory activity at low micromolar or even nanomolar concentrations. These compounds can be classified into metal-chelating active site inhibitors and allosteric inhibitors. Among them, α-hydroxytropolones, N-hydro- xyisoquinolinediones and N-hydroxypyridinediones represent chemotypes active against both HIV and HBV RNases H. In this review we summarize recent developments in the field including the identification of novel RNase H inhibitors, compounds with dual inhibitory activity, broad specificity and efforts to decrease their toxicity. 1. Introduction integrase (IN), and (iii) the proteolytic activity of HIV protease (Menéndez-Arias, 2013). These drugs block viral replication, integra- Reverse-transcribing viruses include important human pathogens, tion and maturation, respectively. In addition, drugs targeting viral such as the human immunodeficiency viruses type 1 and type 2 (HIV-1 entry (e.g. coreceptor antagonists or fusion inhibitors) are used in sal- and HIV-2, respectively) and the hepatitis B virus (Menéndez-Arias vage therapies. Despite the success of antiretroviral therapy, acquired et al., 2017). HIV is the etiological agent of the acquired im- and transmitted drug resistance as well as long-term toxicity pose a munodeficiency syndrome (AIDS). The number of people living with major limitation to the long-term efficacy of current therapies, and HIV worldwide is very high with current estimates ranging between research towards exploiting other targets of antiviral intervention is still 32.7 and 44 million people (average 37.9 million in 2018). Although important for preparedness against future outcomes of the disease. the number of new infections has been steadily declining since the mid- Hepatitis B virus (HBV) infection remains an important cause of 90s, UNAIDS estimates that 1.7 million people got infected in 2018, morbidity and mortality. According to current estimates, there are more while the disease was globally responsible for around 770,000 deaths than 250 million people chronically infected with the virus (www.unaids.org). At present, no vaccine or cure is available, although (MacLachlan and Cowie, 2015; Seto et al., 2018) and twenty to thirty highly active antiretroviral therapy (HAART) has been highly effective percent of the chronically infected adults develop cirrhosis and liver in controlling viral load and preventing the onset of symptoms and cancer (Seto et al., 2018). HBV and associated liver diseases are re- progression to AIDS. sponsible for nearly 900,000 deaths each year, mostly from complica- Most of the currently approved anti-HIV drugs are inhibitors of tions (including cirrhosis and hepatocellular carcinoma) (WHO, 2017). enzymes encoded within the viral genome: (i) DNA polymerase activity Infection and development of chronic disease can be prevented by HBV of HIV reverse transcriptase (RT), (ii) strand transfer activity of HIV vaccination, which is most effective if given within 24 h after birth ∗ Corresponding author. ∗∗ Corresponding author. E-mail addresses: [email protected] (E. Tramontano), [email protected] (L. Menéndez-Arias). https://doi.org/10.1016/j.antiviral.2019.104613 Received 29 August 2019; Received in revised form 18 September 2019; Accepted 19 September 2019 Available online 21 September 2019 0166-3542/ © 2019 Elsevier B.V. All rights reserved. E. Tramontano, et al. Antiviral Research 171 (2019) 104613 (followed by two to three doses at monthly intervals). However, timely synthesis with the removal of the tRNA primer, also catalyzed by the infant vaccination has not been implemented everywhere and despite RNase H. progress, universal coverage is very difficult to achieve (Chang and Reverse transcription shows remarkable differences in HBV com- Nguyen, 2017). On the other hand, available treatments (long-term pared to HIV and other retroviruses (Fig. 1)(Hu and Seeger, 2015; nucleos(t)ide-analogue therapies) are safe and well tolerated, achieve Menéndez-Arias et al., 2017). However, in both viruses the RNase H potent viral suppression, and reduce the incidence of liver-related activity of the viral polymerase plays a prominent role. In HBV reverse complications (Menéndez-Arias et al., 2014; Levrero et al., 2018). transcription, the pregenomic RNA (pgRNA) is extensively degraded However, approved treatments act exclusively on viral replication by during minus-strand DNA synthesis, although the last cleavage occurs inhibiting DNA synthesis catalyzed by the HBV polymerase, and current away from the capped 5′ end, leaving an RNA sequence (direct repeat 1, research focuses on alternative targets for the development of anti-HBV or DR1) that is used as primer for plus-strand DNA synthesis (Nassal, drugs (Pei et al., 2017). 2008; Hu and Seeger, 2015). The RNA primer can also translocate to the Approximately 10% of the HIV-infected population worldwide is DR2 region at the 5’ end of the minus-strand DNA, thereby facilitating coinfected with HBV, although this figure can be higher in several re- the circularization of the DNA genome after the corresponding template gions of Southeast Asia (Singh et al., 2017). HIV reverse transcriptase switch (rcDNA formation). The conversion of rcDNA into covalently and HBV polymerase inhibitors constitute the backbone of antiviral closed circular DNA (cccDNA) involves a series of biochemical events therapies against both pathogens. These drugs block viral DNA synth- including the removal of the 18-nt long RNA primer used in plus- esis during reverse transcription, although an obligatory step in the stranded DNA synthesis, but the molecular mechanisms have not been process involves the degradation of viral RNA by the associated ribo- elucidated and the participation of the viral RNase H is not clear yet nuclease H (RNase H) activity of the HIV and HBV polymerases. To (Hu and Seeger, 2015; Menéndez-Arias et al., 2017). date, RNase H remains as an unexploited target in antiviral interven- tion, and despite efforts to identify specific inhibitors, none of those 3. RNase H function and structure compounds has been approved for clinical use. In this review, we will summarize current knowledge on the structure and catalytic me- RNases H are among the most abundant proteins on our planet. chanism of RNases H, and efforts to discover and develop compounds RNases H bind to RNA/DNA hybrids in a sequence-nonspecific manner targeting the RNase H activity of HIV and HBV. and degrade the RNA strand. Eukaryotic RNase H was initially dis- covered in calf thymus lysates, although its role was unknown for a long 2. RNase H and reverse transcription time (Stein and Hausen, 1969). Its involvement in DNA replication was later suggested after being found in Saccharomyces cerevisiae (Karwan RNases H constitute a family of non-sequence-specific endonuclease and Wintersberger, 1986). enzymes that catalyze the cleavage of RNA in RNA/DNA substrates According to their structural features and evolutionary relation- through a hydrolytic mechanism. Members of the RNase H family can ships, RNases H have been classified into two major groups (RNase H1 be found in nearly all organisms, from bacteria to archaea to eukaryotes or HI and RNase H2 or HII). Arabic numerals have been traditionally (Majorek et al., 2014; Moelling et al., 2017). These enzymes are in- used to designate eukaryotic RNases H (H1 and H2), while Roman volved in many processes such as transposition, replication and repair numbers were assigned to prokaryotic enzymes (RNase HI and HII). of DNA, homologous recombination and RNA-mediated gene silencing. Type 1 RNases H are found in eukaryotic, bacterial and viral proteins, Soon after the discovery of retroviral RTs, its associated RNase H including those associated with RTs (e.g. HIV RT and HBV polymerase). activity was identified as an essential component of the enzyme Type 2 RNases are also found in eukaryotes, as well as in prokaryotes, (Mölling et al., 1971). Retroviral RTs contain DNA polymerase and including archaea. A third related class (designated RNase HIII) and RNase
Load more

Recommended publications
  • Restriction Endonucleases
    Molecular Biology Problem Solver: A Laboratory Guide. Edited by Alan S. Gerstein Copyright © 2001 by Wiley-Liss, Inc. ISBNs: 0-471-37972-7 (Paper); 0-471-22390-5 (Electronic) 9 Restriction Endonucleases Derek Robinson, Paul R. Walsh, and Joseph A. Bonventre Background Information . 226 Which Restriction Enzymes Are Commercially Available? . 226 Why Are Some Enzymes More Expensive Than Others? . 227 What Can You Do to Reduce the Cost of Working with Restriction Enzymes? . 228 If You Could Select among Several Restriction Enzymes for Your Application, What Criteria Should You Consider to Make the Most Appropriate Choice? . 229 What Are the General Properties of Restriction Endonucleases? . 232 What Insight Is Provided by a Restriction Enzyme’s Quality Control Data? . 233 How Stable Are Restriction Enzymes? . 236 How Stable Are Diluted Restriction Enzymes? . 236 Simple Digests . 236 How Should You Set up a Simple Restriction Digest? . 236 Is It Wise to Modify the Suggested Reaction Conditions? . 237 Complex Restriction Digestions . 239 How Can a Substrate Affect the Restriction Digest? . 239 Should You Alter the Reaction Volume and DNA Concentration? . 241 Double Digests: Simultaneous or Sequential? . 242 225 Genomic Digests . 244 When Preparing Genomic DNA for Southern Blotting, How Can You Determine If Complete Digestion Has Been Obtained? . 244 What Are Your Options If You Must Create Additional Rare or Unique Restriction Sites? . 247 Troubleshooting . 255 What Can Cause a Simple Restriction Digest to Fail? . 255 The Volume of Enzyme in the Vial Appears Very Low. Did Leakage Occur during Shipment? . 259 The Enzyme Shipment Sat on the Shipping Dock for Two Days.
    [Show full text]
  • Phosphate Steering by Flap Endonuclease 1 Promotes 50-flap Specificity and Incision to Prevent Genome Instability
    ARTICLE Received 18 Jan 2017 | Accepted 5 May 2017 | Published 27 Jun 2017 DOI: 10.1038/ncomms15855 OPEN Phosphate steering by Flap Endonuclease 1 promotes 50-flap specificity and incision to prevent genome instability Susan E. Tsutakawa1,*, Mark J. Thompson2,*, Andrew S. Arvai3,*, Alexander J. Neil4,*, Steven J. Shaw2, Sana I. Algasaier2, Jane C. Kim4, L. David Finger2, Emma Jardine2, Victoria J.B. Gotham2, Altaf H. Sarker5, Mai Z. Her1, Fahad Rashid6, Samir M. Hamdan6, Sergei M. Mirkin4, Jane A. Grasby2 & John A. Tainer1,7 DNA replication and repair enzyme Flap Endonuclease 1 (FEN1) is vital for genome integrity, and FEN1 mutations arise in multiple cancers. FEN1 precisely cleaves single-stranded (ss) 50-flaps one nucleotide into duplex (ds) DNA. Yet, how FEN1 selects for but does not incise the ss 50-flap was enigmatic. Here we combine crystallographic, biochemical and genetic analyses to show that two dsDNA binding sites set the 50polarity and to reveal unexpected control of the DNA phosphodiester backbone by electrostatic interactions. Via ‘phosphate steering’, basic residues energetically steer an inverted ss 50-flap through a gateway over FEN1’s active site and shift dsDNA for catalysis. Mutations of these residues cause an 18,000-fold reduction in catalytic rate in vitro and large-scale trinucleotide (GAA)n repeat expansions in vivo, implying failed phosphate-steering promotes an unanticipated lagging-strand template-switch mechanism during replication. Thus, phosphate steering is an unappreciated FEN1 function that enforces 50-flap specificity and catalysis, preventing genomic instability. 1 Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
    [Show full text]
  • Redundancy in Ribonucleotide Excision Repair: Competition, Compensation, and Cooperation
    DNA Repair 29 (2015) 74–82 Contents lists available at ScienceDirect DNA Repair j ournal homepage: www.elsevier.com/locate/dnarepair Redundancy in ribonucleotide excision repair: Competition, compensation, and cooperation ∗ Alexandra Vaisman, Roger Woodgate Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-3371, USA a r t i c l e i n f o a b s t r a c t Article history: The survival of all living organisms is determined by their ability to reproduce, which in turn depends Received 1 November 2014 on accurate duplication of chromosomal DNA. In order to ensure the integrity of genome duplication, Received in revised form 7 February 2015 DNA polymerases are equipped with stringent mechanisms by which they select and insert correctly Accepted 9 February 2015 paired nucleotides with a deoxyribose sugar ring. However, this process is never 100% accurate. To fix Available online 16 February 2015 occasional mistakes, cells have evolved highly sophisticated and often redundant mechanisms. A good example is mismatch repair (MMR), which corrects the majority of mispaired bases and which has been Keywords: extensively studied for many years. On the contrary, pathways leading to the replacement of nucleotides Ribonucleotide excision repair with an incorrect sugar that is embedded in chromosomal DNA have only recently attracted significant Nucleotide excision repair attention. This review describes progress made during the last few years in understanding such path- Mismatch repair Ribonuclease H ways in both prokaryotes and eukaryotes. Genetic studies in Escherichia coli and Saccharomyces cerevisiae Flap endonuclease demonstrated that MMR has the capacity to replace errant ribonucleotides, but only when the base is DNA polymerase I mispaired.
    [Show full text]
  • S1 Nuclease Degrades Single-Stranded Nucleic Acids, Releasing 5'-Phosphoryl Mono- Or Oligonucleotides
    Description S1 Nuclease degrades single-stranded nucleic acids, releasing 5'-phosphoryl mono- or oligonucleotides. It is five times more active on DNA than on RNA (1). S1 Nuclease also cleaves dsDNA at the single-stranded region caused by a nick, gap, mismatch or loop. PRODUCT INFORMATION S1 Nuclease exhibits 3’-phosphomonoesterase activity. S1 Nuclease The enzyme is a glycoprotein with a carbohydrate content of 18%. Pub. No. MAN0013722 Applications Rev. Date 29 November 2016 (Rev. A.00) Removal of single-stranded overhangs of DNA #_ fragments (2). S1 transcript mapping (3, 4). Lot: _ Expiry Date: _ Cleavage of hairpin loops. Creation of unidirectional deletions in DNA fragments in Store at -20 °C conjunction with Exo III (5). Source Aspergillus oryzae cells. Components #EN0321 100 U/µL S1 Nuclease 10000 U 5X Reaction Buffer 2 1 mL www.thermofisher.com For Research Use Only. Not for use in diagnostic procedures. Definition of Activity Unit CERTIFICATE OF ANALYSIS One unit of the enzyme produces 1 µg of acid soluble S1 Nuclease was tested for the absence of deoxyribonucleotides in 1 min at 37 °C. contaminating double-stranded DNA specific nuclease Enzyme activity is assayed in the following mixture: activity. 30 mM sodium-acetate (pH 4.5), 50 mM NaCl, 0.1 mM ZnCl2, 5% (v/v) glycerol, 800 µg/mL heat Quality authorized by: Jurgita Zilinskiene denatured calf thymus DNA. Storage Buffer The enzyme is supplied in: 20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.1 mM ZnCl2 and 50% (v/v) glycerol. 5X Reaction Buffer 200 mM sodium acetate (pH 4.5 at 25 °C), 1.5 M NaCl and 10 mM ZnSO4.
    [Show full text]
  • Supporting Information
    Supporting Information Figure S1. The functionality of the tagged Arp6 and Swr1 was confirmed by monitoring cell growth and sensitivity to hydeoxyurea (HU). Five-fold serial dilutions of each strain were plated on YPD with or without 50 mM HU and incubated at 30°C or 37°C for 3 days. Figure S2. Localization of Arp6 and Swr1 on chromosome 3. The binding of Arp6-FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) are compared. The position of Tel 3L, Tel 3R, CEN3, and the RP gene are shown under the panels. Figure S3. Localization of Arp6 and Swr1 on chromosome 4. The binding of Arp6-FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) in the whole chromosome region are compared. The position of Tel 4L, Tel 4R, CEN4, SWR1, and RP genes are shown under the panels. Figure S4. Localization of Arp6 and Swr1 on the region including the SWR1 gene of chromosome 4. The binding of Arp6- FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) are compared. The position and orientation of the SWR1 gene is shown. Figure S5. Localization of Arp6 and Swr1 on chromosome 5. The binding of Arp6-FLAG (top), Swr1-FLAG (middle), and Arp6-FLAG in swr1 cells (bottom) are compared. The position of Tel 5L, Tel 5R, CEN5, and the RP genes are shown under the panels. Figure S6. Preferential localization of Arp6 and Swr1 in the 5′ end of genes. Vertical bars represent the binding ratio of proteins in each locus.
    [Show full text]
  • FAN1 Nuclease Activity Affects CAG Expansion and Age at Onset of Huntington's Disease
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439716; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. McAllister, Donaldson et al FAN1 nuclease activity affects CAG expansion and age at onset of Huntington's disease Branduff McAllister, PhD1+, Jasmine Donaldson, PhD1+, Caroline S. Binda, PhD1, Sophie Powell, BSc1, Uroosa Chughtai, BSc1, Gareth Edwards, PhD1, Joseph Stone, BA1, Sergey Lobanov, PhD1, Linda Elliston, MPhil1, Laura-Nadine Schuhmacher, PhD1, Elliott Rees, PhD1, Georgina Menzies, PhD2, Marc Ciosi, PhD3, Alastair Maxwell, PhD3, Michael J. Chao, PhD4, Eun Pyo Hong, PhD4, Diane Lucente, MS4, Vanessa Wheeler, PhD4, Jong-Min Lee, PhD4,5, Marcy E. MacDonald, PhD4,5, Jeffrey D. Long, PhD6, Elizabeth H. Aylward, PhD7, G. Bernhard Landwehrmeyer, MD PhD8, Anne E. Rosser, MB BChir, PhD9,10, REGISTRY Investigators of the European Huntington’s disease network11, Jane S. Paulsen, PhD12, PREDICT-HD Investigators of the Huntington Study Group13, Nigel M. Williams, PhD1, James F. Gusella, PhD4,5, Darren G. Monckton, PhD3, Nicholas D. Allen, PhD2, Peter Holmans, PhD1, Lesley Jones, PhD1,14* & Thomas H. Massey, BM BCh, DPhil1,15* 1 Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, CF24 4HQ, United Kingdom 2 School of Biosciences, Cardiff University, Cardiff, CF10 3AX,
    [Show full text]
  • Potent Inhibition of Human Telomerase by U-73122
    Journal of Biomedical Science (2006) 13:667–674 667 DOI 10.1007/s11373-006-9100-z Potent inhibition of human telomerase by U-73122 Yi-Jui Chen, Wei-Yun Sheng, Pei-Rong Huang & Tzu-Chien V. Wang* Department of Molecular and Cellular Biology, Chang Gung University, Kwei-San, Tao-Yuan, 333, Taiwan Received 28 April 2006; accepted 14 June 2006 Ó 2006 National Science Council, Taipei Key words: alkylating agents, cancer therapyzU-73122, N-ethylmaleimide, telomerase inhibitor Summary Telomerase activity is repressed in normal human somatic cells, but is activated in most cancers, suggesting that telomerase may be an important target for cancer therapy. In this study, we report that U-73122, an amphiphilic alkylating agent that is commonly used as an inhibitor for phospholipase C, is also a potent and selective inhibitor of human telomerase. The inhibition of telomerase by U-73122 was attributed primarily to the pyrrole-2,5-dione group, since its structural analog U-73343 did not inhibit telomerase. In confirmation, we observed that telomerase was inhibited by N-ethylmaleimide, but not N-ethylsuccinimide. The IC50 value of U-73122 for the in vitro inhibition of telomerase activity is 0.2 lM, which is comparable to or slightly more sensitive than that for phospholipase C. The inhibitory action of U-73122 on telomerase appears to be rather selective since the presence of externally added proteins did not protect the inhibition and the IC50 values for the other enzymes tested in this study were at least an order of magnitude higher than that for telomerase. Furthermore, we demonstrate that U-73122 can inhibit telomerase in hemato- poietic cancer cells.
    [Show full text]
  • Rnase I Manual
    Manual RNase I For Research Use Only. Not for use in diagnostic procedures. RNase I is part of the Epicentre™ product line, known for its unique genomics kits, enzymes, and reagents which offer high quality and reliable performance. Manual RNase I Contents 1. Introduction .......................................................................................................................................3 2. Product designations and kit components ....................................................................................3 3. Product specifications ......................................................................................................................3 4. Protocol for removing RNA from DNA preparations .....................................................................4 5. References .........................................................................................................................................4 6. Further support .................................................................................................................................4 Manual RNase I 1. Introduction RNase I preferentially degrades single-stranded RNA to individual nucleoside 3′ monophosphates by cleaving every phosphodiester bond.1 By comparison, other ribonucleases cleave only after specific residues (e.g., RNase A cleaves 3′ to pyrimidine residues). Thus, RNase I is useful for removing RNA from DNA preparations,2 detecting mismatches in RNA:RNA and RNA:DNA hybrids2,3 and analysing and quantifying RNA in ribonuclease
    [Show full text]
  • Structure and Function of Nucleases in DNA Repair: Shape, Grip and Blade of the DNA Scissors
    Oncogene (2002) 21, 9022 – 9032 ª 2002 Nature Publishing Group All rights reserved 0950 – 9232/02 $25.00 www.nature.com/onc Structure and function of nucleases in DNA repair: shape, grip and blade of the DNA scissors Tatsuya Nishino1 and Kosuke Morikawa*,1 1Department of Structural Biology, Biomolecular Engineering Research Institute (BERI), 6-2-3 Furuedai, Suita, Osaka 565-0874, Japan DNA nucleases catalyze the cleavage of phosphodiester mismatched nucleotides. They also recognize the bonds. These enzymes play crucial roles in various DNA replication or recombination intermediates to facilitate repair processes, which involve DNA replication, base the following reaction steps through the cleavage of excision repair, nucleotide excision repair, mismatch DNA strands (Table 1). repair, and double strand break repair. In recent years, Nucleases can be regarded as molecular scissors, new nucleases involved in various DNA repair processes which cleave phosphodiester bonds between the sugars have been reported, including the Mus81 : Mms4 (Eme1) and the phosphate moieties of DNA. They contain complex, which functions during the meiotic phase and conserved minimal motifs, which usually consist of the Artemis : DNA-PK complex, which processes a V(D)J acidic and basic residues forming the active site. recombination intermediate. Defects of these nucleases These active site residues coordinate catalytically cause genetic instability or severe immunodeficiency. essential divalent cations, such as magnesium, Thus, structural biology on various nuclease actions is calcium, manganese or zinc, as a cofactor. However, essential for the elucidation of the molecular mechanism the requirements for actual cleavage, such as the types of complex DNA repair machinery. Three-dimensional and the numbers of metals, are very complicated, but structural information of nucleases is also rapidly are not common among the nucleases.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Anamika Kothari Quang Ong Ron Caspi An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Peter D Karp Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Csac1394711Cyc: Candidatus Saccharibacteria bacterium RAAC3_TM7_1 Cellular Overview Connections between pathways are omitted for legibility. Tim Holland TM7C00001G0420 TM7C00001G0109 TM7C00001G0953 TM7C00001G0666 TM7C00001G0203 TM7C00001G0886 TM7C00001G0113 TM7C00001G0247 TM7C00001G0735 TM7C00001G0001 TM7C00001G0509 TM7C00001G0264 TM7C00001G0176 TM7C00001G0342 TM7C00001G0055 TM7C00001G0120 TM7C00001G0642 TM7C00001G0837 TM7C00001G0101 TM7C00001G0559 TM7C00001G0810 TM7C00001G0656 TM7C00001G0180 TM7C00001G0742 TM7C00001G0128 TM7C00001G0831 TM7C00001G0517 TM7C00001G0238 TM7C00001G0079 TM7C00001G0111 TM7C00001G0961 TM7C00001G0743 TM7C00001G0893 TM7C00001G0630 TM7C00001G0360 TM7C00001G0616 TM7C00001G0162 TM7C00001G0006 TM7C00001G0365 TM7C00001G0596 TM7C00001G0141 TM7C00001G0689 TM7C00001G0273 TM7C00001G0126 TM7C00001G0717 TM7C00001G0110 TM7C00001G0278 TM7C00001G0734 TM7C00001G0444 TM7C00001G0019 TM7C00001G0381 TM7C00001G0874 TM7C00001G0318 TM7C00001G0451 TM7C00001G0306 TM7C00001G0928 TM7C00001G0622 TM7C00001G0150 TM7C00001G0439 TM7C00001G0233 TM7C00001G0462 TM7C00001G0421 TM7C00001G0220 TM7C00001G0276 TM7C00001G0054 TM7C00001G0419 TM7C00001G0252 TM7C00001G0592 TM7C00001G0628 TM7C00001G0200 TM7C00001G0709 TM7C00001G0025 TM7C00001G0846 TM7C00001G0163 TM7C00001G0142 TM7C00001G0895 TM7C00001G0930 Detoxification Carbohydrate Biosynthesis DNA combined with a 2'- di-trans,octa-cis a 2'- Amino Acid Degradation an L-methionyl- TM7C00001G0190 superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis (E.
    [Show full text]
  • Restriction Enzymes of Bac- Base Teria Combat Foreign Substances
    Understanding Inheritance FESTRICT’K3N ENZYMES J ~ke the immune systems of vertebrate eukaryotes, the restriction enzymes of bac- Base teria combat foreign substances. In particu- Restriction Enzyme Source Organism Sequence of Restriction Site lar, restriction enzymes render the DNA of, BamH 1 Bacillus 5’- ATCC-3’ say, an invading bacteriophage harmless amyloliquefaciens 3’-CCTAG- -5’ by catalyzing its fragmentation, or, more precisely, by catalyzing the breaking of cer- ECORI Escherichia co/i 5’-G ATTC-3’ tain O-P–O– bridges in the backbones of 3’-CTTA5 -5’ each DNA strand. The evolution of restric- tion enzymes helped many species of bac- Hae[[I Haemophi/us aegyptius 5’-G c-3’ teria to survive; their discovery by humans 3’-CC% G-5’ helped precipitate the recombinant-DNA revolution, Hindl[ Haemophi/us influenza 5’-GT(C orT (A or G)AC-3’ 3’-CA(G orA ! (T or C) TG-5’ Three types of restriction enzymes are known, but the term “restriction enzyme” MboI Moraxeila bovis 5’ refers here and elsewhere in this issue to type II restriction endonucleases, the only type commonly used in the study of DNA. (A Notl Nocardia otitidis 5’-G GCCGC nuclease is an enzyme that catalyzes the 3’-CG”CCG% G brealking of -O–P–O- bridges in a string of deoxyribonucleotide or ribonucleotides; an Taql Thermus aquaticus 5’- GA endcmuclease catalyzes the breaking of 3’-AG% internal rather than terminal -O–P–O- bridges.) Many restriction enzymes have beer isolated; more than seventy are avail- man numeral denotes the order of its dis- a sample of human DNA and a sampie of able commercially.
    [Show full text]